# Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)

Study · id `cardio:ct-nct02876835` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02876835](<https://clinicaltrials.gov/study/NCT02876835>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02876835

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3872 participants.

## Technical summary

Registry record NCT02876835. Randomized; no masking; primary purpose treatment. Start 2016-09-27 (actual); primary completion 2021-04-19 (actual). Results posted on 2022-04-14.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 3872 participants (enrolled count; ClinicalTrials.gov record NCT02876835, source copy `cardio:ctgov-nct02876835-2024-04-02`, retrieved 2026-10-26)
- Started: 2016-09-27 (actual) (ClinicalTrials.gov record NCT02876835, source copy `cardio:ctgov-nct02876835-2024-04-02`, retrieved 2026-10-26)
- Primary completion: 2021-04-19 (actual) (ClinicalTrials.gov record NCT02876835, source copy `cardio:ctgov-nct02876835-2024-04-02`, retrieved 2026-10-26)
- Completion: 2021-04-19 (actual) (ClinicalTrials.gov record NCT02876835, source copy `cardio:ctgov-nct02876835-2024-04-02`, retrieved 2026-10-26)
- Results first posted: 2022-04-14 (ClinicalTrials.gov record NCT02876835, source copy `cardio:ctgov-nct02876835-2024-04-02`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Belgium; Brazil; Bulgaria; Canada; Colombia; Czechia; Denmark; Estonia; France; Germany; Greece; Hong Kong SAR China; Hungary; India; Israel; Italy; Malaysia; Mexico; Netherlands; New Zealand; Philippines; Poland; Portugal; Romania; Russia; Singapore; South Africa; South Korea; Spain; Sweden; Taiwan; Thailand; Türkiye; Ukraine; United Kingdom; Vietnam (ClinicalTrials.gov record NCT02876835, source copy `cardio:ctgov-nct02876835-2024-04-02`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02876835-2024-04-02`, retrieved 2026-10-26)

## The registry's words

- Brief title: Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
- Condition: Anaemia
- Intervention (Drug): Daprodustat
- Intervention (Drug): Darbepoetin alfa
- Intervention (Drug): Placebo
- Intervention (Drug): Iron Therapy
- Lead sponsor: GlaxoSmithKline
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: GlaxoSmithKline (`cardio:org-glaxosmithkline`)

## Provenance

Content hash: 9b00828b6dd9570b69ba5b42fee6d3f86892f618666bdc6ddcbaacda73dc87f7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
